DHZB Foundation and Noah Labs sign strategic collaboration and investment agreement
Noah Labs will conduct a groundbreaking clinical study to investigate the potential of voice analysis as a non-invasive and early biomarker in the diagnosis and monitoring of heart failure patients. Around 12 million people in Europe and the US are diagnosed with heart failure, which requires regular treatment and frequent follow-ups[1],[2]. An ageing population and a sharp rise in the prevalence of cardiovascular diseases are contributing to the growing burden of heart failure. The study, which will be conducted at the German Heart Centre at Charité (DHZC) in Berlin, Germany aims to provide new insights into the clinical application and efficacy of voice analysis as a novel diagnostic tool in the management of chronic heart failure. Ultimately, such a solution may help guide therapeutic decisions and reduce the risk of cardiac decompensation.
The collaboration combines the DHZB Foundation's extensive experience in cardiovascular medicine with Noah Labs' groundbreaking machine learning technology and "Noah Labs Ark" platform for location-independent, data-driven care and research. It exemplifies the vibrant environment of the Berlin cluster for healthcare startups in general and cardiovascular technology in particular.
About DHZB Foundation
The Foundation of the German Heart Center Berlin (DHZB) is an independent and private charitable organisation established by the State of Berlin, Germany, to support the capital's role as an international centre of excellence in cardiovascular medicine. Founded in 1985, the DHZB Foundation promotes the advancement of cardiovascular health through excellence in patient care, professional education and technological innovation. Together with Charité Universitätsmedizin Berlin, the Foundation oversees the German Heart Centre at Charité - a leading specialist hospital for cardiology and cardiac surgery. The Foundation also supports education through the DHZB Academy and invests in research and development aimed at the prevention, early diagnosis and more precise treatment of cardiovascular disease. For more information, please visit www.dhzb.org.
About Noah Labs
Noah Labs is a Berlin-based digital health startup. Founded in 2021 by Oliver Weiss, Marcus Hott and Dr. Leonhard Riehle, the company aims to help people with cardiovascular diseases live longer, healthier lives. Marcus previously worked as an AI programmer at Harvard Medical School while Oliver, an economist, previously built the elderly care company Mecasa. Leohard is a medical doctor who previously worked in the field of cardiovascular telemonitoring at Charité Berlin. Noah Labs has 15 employees and is ISO 13485 certified as a manufacturer of (software-based) medical devices. The company is currently conducting clinical trials with Charité in Berlin, the University Medical Centre Maastricht and Clinic Barcelona. Noah Labs is funded by EIT Health and the State of Berlin. It is also a member of the American Heart Association's Center for Health Technology & Innovation.
[1] Groenewegen, A. et al. (2020). Epidemiology of Heart Failure. European Journal ofHeart Failure, 22(8), 1342–1356.
[2] Bozkurt, B.et al. (2023). Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America. Journal of Cardiac Failure, 29 (10), 1412–1451.
The Foundation of the German Heart Center Berlin (DHZB) is an independent and private charitable organisation established by the State of Berlin, Germany, to support the capital's role as an international centre of excellence in cardiovascular medicine. Founded in 1985, the DHZB Foundation promotes the advancement of cardiovascular health through excellence in patient care, professional education and technological innovation. Together with Charité Universitätsmedizin Berlin, the Foundation oversees the German Heart Centre at Charité - a leading specialist hospital for cardiology and cardiac surgery. The Foundation also supports education through the DHZB Academy and invests in research and development aimed at the prevention, early diagnosis and more precise treatment of cardiovascular disease.
At Noah Labs, our AI-powered approach to cardiovascular care and research is dedicated to helping people with cardiovascular disease live longer, healthier lives. The Noah Labs Ark cardiovascular software platform enables cardiologists to efficiently monitor patients with heart failure through telemedicine, utilizing external measurement devices such as smartwatches, blood pressure cuffs, and scales. These devices wirelessly transmit health data to the Noah Labs Ark, where it is continuously analyzed, allowing doctors to detect changes early and respond immediately.
In addition to this, we are developing innovative voice-based machine learning software designed for the early detection of decompensated heart failure - the leading cause of hospitalization. This cutting-edge technology analyzes changes in vocal tone caused by pulmonary edema and fluid accumulation, detecting deterioration up to 14 days before current standard methods. By doing so, it helps avoid costly hospitalizations. Our patented solution is undergoing testing at prestigious institutions including the Mayo Clinic in the USA, Charité in Berlin, and university hospitals in Maastricht and Barcelona.
Founded in 2021 by physician Dr. Leonhard Riehle, machine learning engineer Marcus Hott, and serial entrepreneur Oliver Piepenstock, we are an ISO 13485 certified manufacturer of software-based medical devices, currently employing 20 dedicated professionals.